Metvix

Methyl Aminolevulinate, the active ingredient in Metvix, is a photosensitizing agent presented as a 16% w/w cream for topical use. It treats actinic keratosis, a precancerous skin condition caused by chronic sun exposure, in adult patients with sun‑damaged skin. It is indicated for field‑directed photodynamic therapy performed by dermatologists in clinical settings.

GNH USA supplies Metvix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements, and providing reliable logistics support.

Metvix (methyl aminolevulinate) is used in dermatology for photodynamic therapy of precancerous skin lesions.

Actinic keratosis: provides selective destruction of dysplastic keratinocytes, leading to lesion clearance and reduced risk of progression to squamous cell carcinoma.

Topical application of Metvix followed by light activation can cause a range of local and systemic reactions.

Common Side Effects: - Pain during illumination: transient burning or stinging sensation during light exposure. - Erythema: redness of treated skin lasting several days. - Edema: swelling around the application site. - Crusting/Scaling: formation of crusts or flaky skin as lesions heal.

Serious or Rare Side Effects: - Infection: secondary bacterial infection of treated area. - Ulceration: deep tissue breakdown requiring medical attention. - Scarring: permanent skin changes in severe cases. - Photosensitivity: exaggerated reaction to sunlight after treatment.

Before using Metvix, clinicians should observe several safety measures to minimize adverse events. - Contraindication: avoid use in patients with known porphyria or hypersensitivity to methyl aminolevulinate. - Sunlight avoidance: advise patients to protect treated area from natural light for at least 48 hours post‑treatment. - Lesion selection: ensure lesions are suitable for photodynamic therapy and not infected or heavily hyperkeratotic. - Protective eyewear: require patients and staff to wear appropriate eye protection during illumination. - Monitoring: inspect treated sites for signs of infection or excessive inflammation during follow‑up visits. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and direct sunlight.

Metvix may interact with other agents that influence photosensitivity or skin healing.

Major Interactions (Avoid): - Systemic photosensitizers: concurrent use of drugs such as tetracyclines, sulfonamides, or retinoids can increase phototoxic risk. - UV‑based therapies: combining with other phototherapy modalities may cause excessive skin damage. - Porphyrin‑related disorders: patients with disorders of heme synthesis should not receive methyl aminolevulinate.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may reduce efficacy if applied to the treatment area before or after PDT. - Anticoagulants: monitor for prolonged bleeding if ulceration occurs. - Herbal supplements with photosensitizing properties (e.g., St. John’s wort): advise caution and monitor skin response.